DRR168539
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.400
- MYC_TARGETS_V2+0.390
- TGF_BETA_SIGNALING+0.360
- E2F_TARGETS+0.150
- GLYCOLYSIS+0.070
- DNA_REPAIR+0.050
- G2M_CHECKPOINT+0.050
- UV_RESPONSE_UP+0.050
- MYOGENESIS+0.020
- MITOTIC_SPINDLE+0.000
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.530
- ALLOGRAFT_REJECTION-0.480
- IL6_JAK_STAT3_SIGNALING-0.450
- INFLAMMATORY_RESPONSE-0.360
- COMPLEMENT-0.340
- HEDGEHOG_SIGNALING-0.320
- KRAS_SIGNALING_UP-0.300
- PROTEIN_SECRETION-0.300
- COAGULATION-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1199 | Med | Medulloblastoma | 0.835 |
| 2 | 88306 | EPN | Supratentorial EPN | 0.823 |
| 3 | SRR11296886 | — | — | 0.822 |
| 4 | MDT-AP-0514 | Med | Medulloblastoma | 0.805 |
| 5 | b68594bb-fca3-4f05-a9fa-1e6e88eb4fc5 | — | — | 0.802 |
| 6 | TCGA-BH-A1FL-01A-11R-A13Q-07 | — | B | 0.798 |
| 7 | MDT-AP-0360 | Med | Medulloblastoma | 0.796 |
| 8 | SRR8518365 | — | E | 0.796 |
| 9 | BS_VAAHBH60 | Supratentorial Ependymoma | — | 0.788 |
| 10 | SRR8943005 | — | — | 0.787 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.050 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |